Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting taking place June 21-24, 2025 in New Orleans, Louisiana.

Lead author	Abstract Title	Presentation Details
Stephen Graves	[212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2-positive tumors in the VMT-α-NET-T101 trial	Abstract Number: 251949 Session Type: Poster & Oral Poster Session Date: June 21, 2025 Oral session: MTA07 Oncology: Clinical Diagnosis & Therapy Meet the Author Session, part 2 Oral Session Date: June 23, 2025 Oral Session Time: 12:30 PM - 1:15 PM CDT
Lianbo Zhou	Preclinical evaluation and first-in-human case of [68Ga]Ga-PSV377, a novel cyclic radiopeptide targeting fibroblast activation protein, for positron emission tomography (PET) imaging of multiple cancers	Abstract Number: 251863 Session Type: Poster and Oral Poster Session Date: June 21, 2025 Oral session: MTA06 Oncology: Discovery & Translational Meet the Author Session Oral Session Date: June 23, 2025 Oral Session Time: 10:30 AM - 11:15 AM CDT

[²¹²Pb]VMT-α-NET
This presentation reports on the dosimetry sub-study using [²⁰³Pb]VMT-α-NET as an imaging agent in the ongoing Phase 1/2a clinical trial of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2) positive neuroendocrine tumors (NETs) who have not received a prior radiopharmaceutical therapy (RPT).

The findings of the study suggest that:

• [²¹²Pb]VMT-α-NET dosimetry using [²⁰³Pb]VMT-α-NET as an imaging surrogate is feasible and should be considered as a valuable adjunct to this trial’s clinical data; and
• In general, this dosimetric approach can be a useful, complementary tool in the clinical development of ²¹²Pb-based therapies delivered with Perspective’s proprietary chelator for ²¹²Pb and ²⁰³Pb.

Safety data from the Company’s Phase 1/2a clinical trial of [²¹²Pb]VMT-α-NET demonstrated that [²¹²Pb]VMT-α-NET was well-tolerated among all patients treated, many with long-term follow-up. Therefore, according to the presentation, the reported estimated cumulative absorbed doses of radiation to organs of interest in this analysis likely represent tolerable levels for [²¹²Pb]VMT-α-NET. Dose escalation and further clinical observations are needed to establish the appropriate threshold levels of cumulative absorbed doses and appropriate Relative Biological Effectiveness (RBE) factor of ²¹²Pb delivered with Perspective’s proprietary chelator.